Protective Effect of Previous SARS-CoV-2 Infection against Omicron BA.4 and BA.5 Subvariants.
- Altarawneh, Heba N
- Chemaitelly, Hiam
- Ayoub, Houssein H
- Hasan, Mohammad R
- Coyle, Peter
- Yassine, Hadi M
- Al-Khatib, Hebah A
- Smatti, Maria K
- Al-Kanaani, Zaina
- Al-Kuwari, Einas
- Jeremijenko, Andrew
- Kaleeckal, Anvar H
- Latif, Ali N
- Shaik, Riyazuddin M
- Abdul-Rahim, Hanan F
- Nasrallah, Gheyath K
- Al-Kuwari, Mohamed G
- Butt, Adeel A
- Al-Romaihi, Hamad E
- Al-Thani, Mohamed H
- Al-Khal, Abdullatif
- Bertollini, Roberto
- Tang, Patrick
- Abu-Raddad, Laith J
Publication date
October 2022
DOI Publisher
Massachusetts Medical Society Journal
New England Journal of MedicineAbstract
The BA.4 and BA.5 subvariants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) B.1.1.529 (omicron) variant have shown the capacity of escaping from neutralizing antibodies.1 These subvariants had an appreciable presence in Qatar by early May 2022 (Fig. S1 in the Supplementary Appendix, available with the full text of this letter at NEJM.org) and had become the dominant subvariants by June 8 (Fig. S2). We estimated the effectiveness of previous SARS-CoV-2 infection in preventing reinfection with BA.4 and BA.5 subvariants using a test-negative, case–control study design (Section S1).
Add to ORKG